Cell Therapeutics, Inc. Reports Third Quarter 2013 Financial Results
Published: Oct 31, 2013
SEATTLE, Oct. 30, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the third quarter and nine months ended September 30, 2013.
"We recently achieved an important clinical milestone in our pacritinib development program, having reached agreement with the FDA on a Special Protocol Assessment (SPA) for the planned pivotal Phase 3 PERSIST-2 clinical trial of pacritinib for patients with myelofibrosis who have low platelet counts," said James Bianco, M.D., President and CEO of CTI.
Help employers find you! Check out all the jobs and post your resume.